Tina Nova compensation by year
VERACYTE Summary Compensation Table · the one fiscal year held| Component | FY2022 |
|---|---|
| Salary | $500,000 |
| Bonus | $0 |
| Stock awards | $2,206,990 |
| Option awards | $1,476,039 |
| Non-equity incentive | $412,500 |
| Pension and deferred compensation | $0 |
| All other | $3,000 |
| Total | $4,598,529 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: VERACYTE, INC. DEF 14A filed April 27, 2023, accession 0001384101-23-000055, and prior-year filings. Open the filing on EDGAR.
How this page was built: the VERACYTE, INC. filed document, accession 0001384101-23-000055. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 56,546 | $1,341,837 | — |
| PSU | 28,273 | $670,918 | — |
| Option | 37,773 | — | $26.02 |
Per the Outstanding Equity Awards at Fiscal Year-End table in VERACYTE, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
VERACYTE’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $4,935,422 |
| Tina Nova · this page | General Manager, Decipher Urologic Cancers | $4,598,529 |
| Giulia Kennedy | Former Global Chief Scientific and Chief Medical Officer | $4,533,563 |
| Rebecca Chambers | Chief Financial Officer | $3,322,756 |
| Annie McGuire | General Counsel and Chief People Officer | $2,447,055 |
Board service
VERACYTE board · FY2021| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2021 | $4,583 | $0 | — | — | $4,583 |
Each year as the company reported it in VERACYTE's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: VERACYTE pays directors a $50,000 cash retainer and $250,000 in equity. As stated in VERACYTE's FY2025 proxy.
The full VERACYTE compensation record
free company briefThis page is one person within VERACYTE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the VERACYTE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are VERACYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.